- Home
- ZVIA vs ESPR Comparison
ZVIA vs ESPR Comparison
Compare ZVIA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- ESPR
- Stock Information
- Founded
- ZVIA 2007
- ESPR 2008
- Country
- ZVIA United States
- ESPR United States
- Employees
- ZVIA N/A
- ESPR N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ZVIA Consumer Staples
- ESPR Health Care
- Exchange
- ZVIA Nasdaq
- ESPR Nasdaq
- Market Cap
- ZVIA 204.8M
- ESPR 208.1M
- IPO Year
- ZVIA 2021
- ESPR 2013
- Fundamental
- Price
- ZVIA $3.11
- ESPR $1.15
- Analyst Decision
- ZVIA Hold
- ESPR Buy
- Analyst Count
- ZVIA 2
- ESPR 6
- Target Price
- ZVIA $3.38
- ESPR $6.50
- AVG Volume (30 Days)
- ZVIA 1.0M
- ESPR 3.3M
- Earning Date
- ZVIA 08-06-2025
- ESPR 08-11-2025
- Dividend Yield
- ZVIA N/A
- ESPR N/A
- EPS Growth
- ZVIA N/A
- ESPR N/A
- EPS
- ZVIA N/A
- ESPR N/A
- Revenue
- ZVIA $154,273,000.00
- ESPR $259,574,000.00
- Revenue This Year
- ZVIA $5.66
- ESPR $4.07
- Revenue Next Year
- ZVIA $6.76
- ESPR N/A
- P/E Ratio
- ZVIA N/A
- ESPR N/A
- Revenue Growth
- ZVIA N/A
- ESPR 12.99
- 52 Week Low
- ZVIA $0.62
- ESPR $0.69
- 52 Week High
- ZVIA $4.99
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ZVIA 52.91
- ESPR 59.60
- Support Level
- ZVIA $3.00
- ESPR $0.95
- Resistance Level
- ZVIA $3.66
- ESPR $1.06
- Average True Range (ATR)
- ZVIA 0.28
- ESPR 0.07
- MACD
- ZVIA -0.00
- ESPR -0.01
- Stochastic Oscillator
- ZVIA 52.56
- ESPR 74.07
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.